Monoamine oxidase inhibitors are used to treat which of the following?

Choice A reason: Persistent depressive disorder responds better to SSRIs or psychotherapy, as MAOIs’ risk of hypertensive crises due to monoamine buildup limits their use. MAOIs increase serotonin, dopamine, and norepinephrine, but are reserved for severe cases due to complex neural interactions. Choice B reason: MAOIs like phenelzine are used for treatment-resistant depression, where SSRIs fail, by increasing serotonin, dopamine, and norepinephrine via enzyme inhibition. This broad monoamine enhancement alters prefrontal-amygdala circuits, addressing severe depressive symptoms unresponsive to other treatments, making it the primary indication. Choice C reason: Moderate depression is typically treated with SSRIs or SNRIs, which have safer profiles. MAOIs’ risk of serotonin and norepinephrine overload, causing hypertensive crises, makes them unsuitable for moderate cases, where less aggressive neural modulation is effective. Choice D reason: Mild depression is managed with psychotherapy or SSRIs, not MAOIs, which risk serious side effects like tyramine-induced hypertensive crises due to excessive monoamine levels. MAOIs are reserved for severe, resistant cases, not mild neural dysregulation.